drugset / Trial / NCT00796796

Temsirolimus and Radiation for Non-Small Cell Lung Cancer

NCT00796796

Phase 1 Completed 10 enrolled Washington University School of Medicine
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To determine the maximum tolerated dose of the drug temsirolimus given with radiation therapy for patients with non-small cell lung cancer.

Timeline

Start
2009-03
Primary completion
2011-06
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Temsirolimus Small molecule 20 mg Intravenous
Subject Temsirolimus Small molecule 25 mg Intravenous